A bill that aims to curb product hopping, patent thickets and other tactics brand drug makers use to delay generic and biosimilar market entry is now projected to save the government roughly $3 billion, nearly $2 billion more than what the Congressional Budget Office (CBO) projected back in 2022. The jump in savings for this -- combined with two other drug competition and patent reform bills estimated to jointly save over $2 billion -- may significantly increase the likelihood of...